Shows & Panels
- The 2014 Big Picture on Cyber Security
- AFCEA Answers
- Ask the CIO
- Building the Hybrid Cloud
- Connected Government: How to Build and Procure Network Services for the Future
- Continuing Diagnostics and Mitigation: Discussion of Progress and Next Steps
- Federal Executive Forum
- Federal Tech Talk
- The Future of Government Data Centers
- The Future of IT: How CIOs Can Enable the Service-Oriented Enterprise
- The Intersection: Where Technology Meets Transformation
- Maximizing ROI Through Data Center Consolidation
- Mitigating Insider Threats in Virtual & Cloud Environments
- Modern Mission Critical Series
- Moving to the Cloud. What's the best approach for me
- Navigating Tough Choices in Government Cloud Computing
- The New Generation of Database
- Satellite Communications: Acquiring SATCOM in Tight Times
- Targeting Advanced Threats: Proven Methods from Detection through Remediation
- Transformative Technology: Desktop Virtualization in Government
- The Truth About IT Opex and Software Defined Networking
- Value of Health IT
- Air Traffic Management Transformation Report
- Cloud First Report
- General Dynamics IT Enterprise Center
- Gov Cloud Minute
- Government in Technology Series
- Homeland Security Cybersecurity Market Report
- National Cybersecurity Awareness Month
- Technology Insights
- The Cyber Security Report
- The Next Generation Cyber Security Experts
Shows & Panels
FDA warns of massive diabetes test strip recall
Wednesday - 7/31/2013, 5:40pm EDT
WASHINGTON (AP) -- The Food and Drug Administration is warning patients with diabetes about a recall of up to 62 million glucose test strips used to measure blood sugar levels that can show incorrect, abnormally high blood sugar readings.
Nova Diabetes Care announced the recall Friday. An incorrect reading could potentially lead to dangerous medication errors for patients.
The strips covered by the recall are marketed under the brand names Nova Max Blood Glucose Test Strips and Nova Max Plus Glucose Meter Kits. The recall affects certain lots of the strips distributed in the U.S., Canada, Chile, Peru, Argentina, the Dominican Republic, Jamaica and a half-dozen other countries. Nova Diabetes Care sells them through retail stores and websites.
The FDA said Wednesday that the strips are contaminated with a chemical used in the manufacturing process, which interferes with readings. FDA regulators are working with the company to investigate the problem and make sure it is corrected.
Patients can visit a company website to check if their glucose test strips are affected by the recall: www.novacares.com/news/nova-max-recall.php . They can also call a company hotline at 1-800-681-7390. Customers can return the strips and receive replacements at no charge.
Doctors and patients should pay attention for signs and symptoms of high or low blood sugar levels, including excessive thirst, nausea, weakness, headaches and trembling.
"It is important that patients using these test strips discontinue their use immediately," said Alberto Gutierrez, director of FDA's office of in vitro diagnostics. "A false reading could result in patient harm and delay critical care."
On the Web: http://www.novacares.com/news/nova-max-recall.php
Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.